Venezuela lawmakers elect Chavez ally as Assembly chief


CARACAS (Reuters) - Venezuelan lawmakers re-elected a staunch ally of Hugo Chavez to head the National Assembly on Saturday, putting him in line to be caretaker president if the socialist leader does not recover from cancer surgery.


By choosing the incumbent, Diosdado Cabello, the "Chavista"-dominated legislature cemented the combative ex-soldier's position as the third most powerful figure in the government, after Chavez and Vice President Nicolas Maduro.


"As a patriot ... I swear to be supremely loyal in everything I do, to defend the fatherland, its institutions, and this beautiful revolution led by our Comandante Hugo Chavez," Cabello said as he took the oath, his hand on the constitution.


He had earlier warned opposition politicians against attempting to use the National Assembly to "conspire" against the people, saying they would be "destroyed" if they tried.


Thousands of the president's red-clad supporters gathered outside parliament hours before the vote, many chanting: "We are all Chavez! Our comandante will be well! He will return!"


If Chavez had to step down, or died, Cabello would take over the running of the country as Assembly president and a new election would be organized within 30 days. Chavez's heir apparent, Maduro, would be the ruling Socialist Party candidate.


Chavez, who was diagnosed with an undisclosed form of cancer in his pelvic area in mid-2011, has not been seen in public nor heard from in more than three weeks.


Officials say the 58-year-old is in delicate condition and has suffered multiple complications since the December 11 surgery, including unexpected bleeding and severe respiratory problems.


Late on Friday, Maduro gave the clearest indication yet that the government was preparing to delay Chavez's inauguration for a new six-year term, which is scheduled for Thursday.


'CHAVEZ IS PRESIDENT'


Maduro said the ceremony was a "formality" and that Chavez could be sworn in by the Supreme Court at a later date.


The opposition says Chavez's absence would be just the latest sign that he is no longer fit to govern, and that new elections should be held in the South American OPEC nation.


Brandishing a copy of the constitution after his win in the Assembly, Cabello slammed opposition leaders for writing a letter to foreign embassies in which they accused the government of employing a "twisted reading" of the charter.


"Get this into your heads: Hugo Chavez was elected president and he will continue to be president beyond January 10. No one should have any doubt ... this is the constitutional route," he said as fellow Socialist Party lawmakers cheered.


The opposition sat stony-faced. One of their legislators had earlier told the session that it was not just the head of state who was ill, "the republic is sick."


Last year, Chavez staged what appeared to be a remarkable comeback from the disease to win re-election in October, despite being weakened by radiation therapy. He returned to Cuba for more treatment within weeks of his victory.


Should the president have to step down after 14 years in office, a new vote would probably pit Maduro, a 50-year-old former bus driver and union leader, against opposition leader Henrique Capriles, the 40-year-old governor of Miranda state.


Capriles lost to Chavez in October's presidential election.


"I don't think Maduro would last many rounds in a presidential race. He's not fit for the responsibility they have given him," Capriles said after the vice president's appearance on state television.


Chavez's condition is being watched closely by leftist allies around Latin American who have benefited from his oil-funded generosity, as well as investors attracted by Venezuela's lucrative and widely traded debt.


The country boasts the world's biggest crude reserves. Despite the huge political upheaval Chavez's exit would cause, the oil industry is not likely to be affected much in the short term, with an extension of "Chavismo" keeping projects on track, while a change in parties could usher in more foreign capital.


(Additional reporting by Deisy Buitrago; Editing by Vicki Allen)



Read More..

Football: Wolves sack Solbakken after FA Cup exit






LONDON: Stale Solbakken was sacked as manager of Championship side Wolves on Saturday, just hours after the club had been dumped out of the FA Cup by non-league Luton.

The struggling side, who were relegated from the Premier League last season, also terminated the contracts of assistant manager Johan Lange and Patrick Weiser, the first team coach.

Wolves are currently 18th in the Championship, having won just three out of their last 16 league games and a disappointing run of results culminated in Saturday's FA Cup third round 1-0 defeat to Luton Town.

Solbakken had only been in charge at Molineux for six months.

"Kevin Thelwell, head of football development and recruitment, will take charge of first team training until a new manager is appointed, assisted by development coach, Steve Weaver," said a club statement.

"The club would like to offer their thanks and best wishes to Stale, Johan and Patrick."

The 44-year-old Solbakken, who had previously been in charge of German side Cologne, replaced Terry Connor in the Wolves hotseat last summer.

He becomes the 10th Championship manager to leave his club this season while Wolves now search for their fourth boss in under a year.

Speaking after Saturday's match, the Norwegian had said he was not "embarrassed" by the defeat.

"There will be a lot of questions over me but that is normal, that's football and I have to take that, it's no problem," he said.

"I can put it right. I'm not embarrassed by the result, I can't fault the players' effort. First half we did well, but second half we didn't because our physical presence in the box was not enough."

- AFP/de



Read More..

Prices double as private vaccines flood market

NEW DELHI: The Universal Immunisation Programme (UIP) seems to have slipped almost entirely into the grip of the private sector as the government's vaccine institutes that were reopened in February 2010 after being shut down two years ago are yet to contribute in any significant way. In the process, the cost of most vaccines has more than doubled since 2006-07.

Barring oral polio vaccine, the cost of other routine vaccines that added up to a little over a quarter of the annual routine immunization budget has increased to account for more than 50% of the entire budget, shows the response to an RTI application filed with the Vaccine Procurement Cell in the health ministry by Dr K V Babu, central council member of the Indian Medical Association.

In 2006-07, over 90% of the DPT (diphtheria, pertussis, tetanus) vaccine doses and over 80% of the tetanus toxoid vaccine used for UIP were supplied by the Pasteur Institute of India (PII) in Coonoor and the Central Research Institute (CRI) in Kasauli. In 2012-13, the two institutes together barely produced 36% of the DPT vaccines used and 23% of the TT vaccine used for the UIP.

The price of DPT vaccine has more than doubled between 2006-07 and 2012, going up from Rs 12 to Rs 28 per vial of ten doses. Similarly, the price of TT vaccine has gone up from Rs 6 to Rs 15.

The BCG Vaccine Laboratory in Guindy, Chennai was the sole supplier of BCG vaccine for the UIP. The government is now entirely dependent on the private sector as no other government institute produces BCG vaccine. The two other manufacturers of BCG vaccine, Serum Institute of India (SII) in Pune and Green Signal Bio-Pharma Ltd in Chennia, are private companies. Since 2008, the price of BCG has gone up from Rs 13 to Rs 30 per vial of ten doses.

Interestingly, the least increase in cost has been in the case of measles, where prices have risen by less than 25% despite the demand for doses in 2012-13 being five times what it was in 2006-07. Perhaps it is no coincidence that the measles vaccine was the one that already had a private monopoly even in 2006-07.

The three government institutes, which produced the bulk of the vaccines required for the basic immunisation programme against six diseases, were shut down in 2008 reportedly for not being compliant with good manufacturing practices (GMP) by then health minister Anbumani Ramadoss. This move was sharply criticised by the parliamentary standing committee on health and family welfare which observed that it was the government's responsibility to invest in its own institutes to ensure they were GMP complaint instead of using that as an excuse to shut them down leaving the UIP at the mercy of the private sector.

Though all three institutes were reopened in February 2010, so far, the BCG Vaccine Laboratory has not produced a single dose of vaccine for the immunisation programme and PII Coonoor and CRI Kasauli have been producing a fraction of what they used to supply earlier.

The two other vaccines in the basic UIP are OPV and measles vaccine. For the measles vaccine, the RTI reply of the vaccine procurement unit of the ministry lists only one supplier, the Serum Institute of India in Pune, though the Central Bureau of Health Intelligence (CBHI) lists Indian Immunological Ltd and Human Biologicals Institute, two government units, as suppliers too. However, they do not seem to produce any significant amount. A measles vaccine dose currently costs the government over Rs 10.

In the case of OPV vaccine, the biggest suppliers seem to be two private companies Panacea Biotech Ltd and Bharat Biotech International Ltd in Hyderabad, which seem to meet the bulk of the demand. Though BIBCOl Bulandshahr, a government institute, and Haffkine Biopharmaceutical Ltd in Mumbai, a public sector unit (PSU), are listed as producers of OPV, their contribution seems negligible, going by the data of the CBHI.

The government units which made an insignificant contribution to the UIP were not chosen for being closed down. It is the units which contributed to a large share of the immunisation programme's demand that were shut down, resulting in the entire market for the vaccines produced by these units being turned over to the private companies.

Read More..

City Answers Gang-Rape Cover-Up Allegations












As Steubenville, Ohio, prepares for the high-profile rape trial of two high school football players, officials, battling allegations of a cover-up, announced the creation of a new website today to debunk rumors and create what they said would be a transparent resource for the community.


"This site is not designed to be a forum for how the Juvenile Court ought to rule in this matter," the website, called Steubenville Facts, said.


A timeline of the case, beginning with the alleged gang rape of a 16-year-old girl at a party on Aug. 11-12, 2012, is posted on the site. Summaries of Ohio law relating to the case and facts about the local police force including statistics on how many graduated from Steubenville schools, is included.


The case gained national attention last week when hacking collective Anonymous leaked a video of Steubenville high school athletes mocking the 16-year-old female victim and making crude references to the alleged rape.






Steubenville Herald-Star, Michael D. McElwain/AP Photo







"It's disgusting, and I've had people calling, numerous people call here, upset, they have seen it, one woman, two women were crying, because of what they witnessed," Jefferson County Sheriff Fred Abdalla said. "It really is disgusting to watch that video."


Anonymous has called for more arrests, however Steubenville Police have said their hands are tied.


"Steubenville Police investigators are caring humans who recoil and are repulsed by many of the things they observe during an investigation," the website said, addressing the video. "Like detectives in every part of America and the world, they are often frustrated when they emotionally want to hold people accountable for certain detestable behavior but realize that there is no statute that allows a criminal charge to be made."


Occupy Steubenville, a grassroots group, estimated 1,300 people attended a rally today outside the Jefferson County Courthouse, where rape victims and their loved ones gathered to share their stories.


The father of a teenage rape victim was met with applause when he shared his outrage.


"I've tried to show my girl that not all men are like this, but only a despicable few," he said. "And their mothers that ignore the truth that they gave birth to a monster."


Authorities investigated the case and charged two Steubenville high school athletes on Aug. 22, 2012.


The teenagers face trial on Feb. 13, 2013 in juvenile court before a visiting judge.


Attorneys for the boys have denied charges in court.



Read More..

FDA: New rules will make food safer


WASHINGTON (AP) — The Food and Drug Administration says its new guidelines would make the food Americans eat safer and help prevent the kinds of foodborne disease outbreaks that sicken or kill thousands of consumers each year.


The rules, the most sweeping food safety guidelines in decades, would require farmers to take new precautions against contamination, to include making sure workers' hands are washed, irrigation water is clean, and that animals stay out of fields. Food manufacturers will have to submit food safety plans to the government to show they are keeping their operations clean.


The long-overdue regulations could cost businesses close to half a billion dollars a year to implement, but are expected to reduce the estimated 3,000 deaths a year from foodborne illness. The new guidelines were announced Friday.


Just since last summer, outbreaks of listeria in cheese and salmonella in peanut butter, mangoes and cantaloupe have been linked to more than 400 illnesses and as many as seven deaths, according to the federal Centers for Disease Control and Prevention. The actual number of those sickened is likely much higher.


Many responsible food companies and farmers are already following the steps that the FDA would now require them to take. But officials say the requirements could have saved lives and prevented illnesses in several of the large-scale outbreaks that have hit the country in recent years.


In a 2011 outbreak of listeria in cantaloupe that claimed 33 lives, for example, FDA inspectors found pools of dirty water on the floor and old, dirty processing equipment at Jensen Farms in Colorado where the cantaloupes were grown. In a peanut butter outbreak this year linked to 42 salmonella illnesses, inspectors found samples of salmonella throughout Sunland Inc.'s peanut processing plant in New Mexico and multiple obvious safety problems, such as birds flying over uncovered trailers of peanuts and employees not washing their hands.


Under the new rules, companies would have to lay out plans for preventing those sorts of problems, monitor their own progress and explain to the FDA how they would correct them.


"The rules go very directly to preventing the types of outbreaks we have seen," said Michael Taylor, FDA's deputy commissioner for foods.


The FDA estimates the new rules could prevent almost 2 million illnesses annually, but it could be several years before the rules are actually preventing outbreaks. Taylor said it could take the agency another year to craft the rules after a four-month comment period, and farms would have at least two years to comply — meaning the farm rules are at least three years away from taking effect. Smaller farms would have even longer to comply.


The new rules, which come exactly two years to the day President Barack Obama's signed food safety legislation passed by Congress, were already delayed. The 2011 law required the agency to propose a first installment of the rules a year ago, but the Obama administration held them until after the election. Food safety advocates sued the administration to win their release.


The produce rule would mark the first time the FDA has had real authority to regulate food on farms. In an effort to stave off protests from farmers, the farm rules are tailored to apply only to certain fruits and vegetables that pose the greatest risk, like berries, melons, leafy greens and other foods that are usually eaten raw. A farm that produces green beans that will be canned and cooked, for example, would not be regulated.


Such flexibility, along with the growing realization that outbreaks are bad for business, has brought the produce industry and much of the rest of the food industry on board as Congress and FDA has worked to make food safer.


In a statement Friday, Pamela Bailey, president of the Grocery Manufacturers Association, which represents the country's biggest food companies, said the food safety law "can serve as a role model for what can be achieved when the private and public sectors work together to achieve a common goal."


The new rules could cost large farms $30,000 a year, according to the FDA. The agency did not break down the costs for individual processing plants, but said the rules could cost manufacturers up to $475 million annually.


FDA Commissioner Margaret Hamburg said the success of the rules will also depend on how much money Congress gives the chronically underfunded agency to put them in place. "Resources remain an ongoing concern," she said.


The farm and manufacturing rules are only one part of the food safety law. The bill also authorized more surprise inspections by the FDA and gave the agency additional powers to shut down food facilities. In addition, the law required stricter standards on imported foods. The agency said it will soon propose other overdue rules to ensure that importers verify overseas food is safe and to improve food safety audits overseas.


Food safety advocates frustrated over the last year as the rules stalled praised the proposed action.


"The new law should transform the FDA from an agency that tracks down outbreaks after the fact, to an agency focused on preventing food contamination in the first place," said Caroline Smith DeWaal of the Center for Science in the Public Interest.


Read More..

Abbas sees Palestinian unity as Fatah rallies in Gaza


GAZA (Reuters) - President Mahmoud Abbas predicted the end of a five-year split between the two big Palestinian factions as his Fatah movement staged its first mass rally in Gaza with the blessing of Hamas Islamists who rule the enclave.


"Soon we will regain our unity," Abbas, whose authority has been limited to the Israeli-occupied West Bank since the 2007 civil war between the two factions, said in a televised address to hundreds of thousands of followers marching in Gaza on Friday, with yellow Fatah flags instead of the green of Hamas.


The hardline Hamas movement, which does not recognize Israel's right to exist, expelled secular Fatah from Gaza during the war. It gave permission for the rally after the deadlock in peace talks between Abbas's administration and Israel narrowed the two factions' ideological differences.


The Palestinian rivals have drawn closer since Israel's assault on Gaza assault in November, in which Hamas, though battered, claimed victory.


Egypt has long tried to broker Hamas-Fatah reconciliation, but past efforts have foundered over questions of power-sharing, control of weaponry, and to what extent Israel and other powers would accept a Palestinian administration including Hamas.


An Egyptian official told Reuters Cairo was preparing to invite the factions for new negotiations within two weeks.


Israel fears grassroots support for Hamas could eventually topple Abbas's Palestinian Authority (PA) in the West Bank.


"Hamas could seize control of the PA any day," Israeli Prime Minister Benjamin Netanyahu said on Thursday.


The demonstration marked 48 years since Fatah's founding as the spearhead of the Palestinians' fight against Israel. Its longtime leader Yasser Arafat signed an interim 1993 peace accord that won Palestinians a measure of self rule.


Hamas, which rejected the 1993 deal, fought and won a Palestinian parliamentary election in 2006. It formed an uneasy coalition with Fatah until their violent split a year later.


Though shunned by the West, Hamas feels bolstered by electoral gains for Islamist movements in neighboring Egypt and elsewhere in the region - a confidence reflected in the fact Friday's Fatah demonstration was allowed to take place.


"The success of the rally is a success for Fatah, and for Hamas too," said Hamas spokesman Sami Abu Zuhri. "The positive atmosphere is a step on the way to regain national unity."


Fatah, meanwhile, has been riven by dissent about the credibility of Abbas's statesmanship, especially given Israel's continued settlement-building on West Bank land. The Israelis quit Gaza unilaterally in 2005 after 38 years of occupation.


"The message today is that Fatah cannot be wiped out," said Amal Hamad, a member of the group's ruling body, referring to the demonstration attended by several Abbas advisers. "Fatah lives, no one can exclude it and it seeks to end the division."


In his speech, Abbas promised to return to Gaza soon and said Palestinian unification would be "a step on the way to ending the (Israeli) occupation".


(Editing by Dan Williams, Alistair Lyon and Jason Webb)



Read More..

Tennis: Tsonga withdraws from Sydney event with injury






SYDNEY, Jan 5, 2013 (AFP) - French tennis star Jo-Wilfried Tsonga has withdrawn from next week's Sydney International with a hamstring injury, tournament organisers said on Saturday.

The world number eight pulled out of the last major lead-up event to this month's Australian Open after suffering the injury playing for France in the mixed teams Hopman Cup in Perth on Friday.

"Unfortunately Jo-Wilfried Tsonga sustained an injury in Perth and has been forced to pull out of the Apia International Sydney with a left hamstring injury," tournament director Craig Watson said.

"We wish him a speedy recovery and all the best for a successful Australian Open."

Tsonga became the second top seed to drop out of the Sydney event after French compatriot Richard Gasquet, the world number 10, pulled out for personal reasons, organisers said.

- AFP/fa



Read More..

Centre seeks proposals on CCTV inside state buses

NEW DELHI: Centre has asked the state public transport corporations to send proposals on installing CCTV cameras inside their buses and setting up of monitoring station for keep track of the bus movements even on rural routes. Based on their fund requirement, the Centre would step in to provide financial assistance for vehicle and passenger safety.

The proposal was made on Thursday at the executive committee meeting of Association of State Road Transport Undertakings (ARSTUs) under the chairmanship of Union road transport secretary AK Upadhyaya. Sources said that the ministry is keen to provide aid to the STUs under its scheme to implement IT initiatives for better functioning of government owned public buses.

"We will send our proposals. Installation of CCTVs inside buses to keep eye on the activities is a good move, but we need to have proper monitoring centres. Moreover you need to be linked to local police so that they can take action in case of an emergency," said a senior official of a state transport corporation from south India said. He added that most of the major STUs operating buses in cities are going for global positioning system (GPS).

Mumbai's BEST and Andhra's APSRTC are some of the main corporations which are showing interest in this regard. The need for GPS and monitoring has gained importance due to the recent national uprising for women safety.

Sources said in the past two fiscal years, the road transport ministry has sanctioned Rs 71 crore to 15 SRTUs for IT projects. These transport bodies are investing another Rs 71 crores to implement the projects. ARSTU officials said another 30-40 transport corporations want the tracking system and to have a monitoring centre.

Read More..

Obama Poised to Name New Defense, Treasury Chiefs













With the "fiscal cliff" crisis behind him, President Obama is poised to name two new key players to his cabinet, with both announcements expected to come next week.


Obama will name the replacement for outgoing Defense Secretary Leon Panetta as soon as Monday, sources told ABC News. Former Republican Sen. Chuck Hagel is the likely nominee, they said.


Meanwhile, the president is also eyeing a replacement for outgoing Treasury Secretary Timothy Geithner, the longest-serving member of Obama's first-term economic team and one-time lead negotiator for the administration in the "fiscal cliff" talks.


Current chief of staff Jack Lew is all but certain to get the nod for Treasury, according to people familiar with Obama's thinking.


A White House spokesman cautioned that the president has not yet made a final decision on either post, calling reports about Hagel and Lew "merely guessing."


Still, when Obama returns from his Hawaiian vacation on Sunday, he's expected to waste little time filling out his team for a second term.


Geithner has said he would remain at his post "until around the inauguration" Jan. 20, a Treasury spokesperson said Thursday, putting the department potentially in transition just as the administration confronts the next financial "cliffs" over automatic spending cuts and the nation's debt limit.






Brendan Hoffman/Getty Images











3 Dead After Plane Crashes Into Florida Home Watch Video









Pilot Arrested After Failing Breathalyzer Test Watch Video









Colorado Police Officers on Leave After Killing Elk Watch Video





During an appearance on ABC's "This Week" in April, Geithner said the next Treasury secretary would need to be someone who is "willing to tell [Obama] the truth and, you know, help him do the tough things you need to do."


Lew, a former two-time Office of Management and Budget director and trusted Obama confidant who has held the chief of staff role since early 2012, is the front-runner for the job.


Meanwhile, Sen. John Kerry -- Obama's nominee to replace outgoing Secretary of State Hillary Clinton -- has begun making more regular appearances at the U.S. State Department before his expected confirmation later this month.


His Senate hearings are set to begin shortly after Obama's inauguration, sources say. The administration still expects Clinton to testify about the Sept. 11 Benghazi, Libya, attacks before Kerry is confirmed.


But it is the potential nomination of Republican Hagel that has caused the most stir.


Critics from across the political spectrum have taken aim at the former senator from Nebraska's record toward Israel and what some have called a lack of experience necessary to lead the sprawling Pentagon bureaucracy or its operations. The controversy has set the stage for what would be a contentious confirmation process.


"A lot of Republicans and Democrats are very concerned about Chuck Hagel's position on Iran sanctions, his views toward Israel, Hamas and Hezbollah, and that there is wide and deep concern about his policies," Sen. Lindsey Graham, R-S.C., told "Fox News Sunday."


He would not say whether Republicans felt so strongly as to expect a filibuster of the nomination.


"I can tell you there would be very little Republican support for his nomination," Graham said. "At the end of the day, they will be very few votes."


Still, Hagel, 66, a former businessman and decorated veteran who served in the Vietnam War, has won praise and admiration from current and former diplomats for his work on Obama's Intelligence Advisory Board and Panetta's Policy Advisory Board.





Read More..

Indian court to rule on generic drug industry


NEW DELHI (AP) — From Africa's crowded AIDS clinics to the malarial jungles of Southeast Asia, the lives of millions of ill people in the developing world are hanging in the balance ahead of a legal ruling that will determine whether India's drug companies can continue to provide cheap versions of many life-saving medicines.


The case — involving Swiss drug maker Novartis AG's cancer drug Glivec — pits aid groups that argue India plays a vital role as the pharmacy to the poor against drug companies that insist they need strong patents to make drug development profitable. A ruling by India's Supreme Court is expected in early 2013.


"The implications of this case reach far beyond India, and far beyond this particular cancer drug," said Leena Menghaney, from the aid group Doctors Without Borders. "Across the world, there is a heavy dependence on India to supply affordable versions of expensive patented medicines."


With no costs for developing new drugs or conducting expensive trials, India's $26 billion generics industry is able to sell medicine for as little as one-tenth the price of the companies that developed them, making India the second-largest source of medicines distributed by UNICEF in its global programs.


Indian pharmaceutical companies such as Cipla, Cadila Laboratories and Lupin have emerged over the past decade as major sources of generic cancer, malaria, tuberculosis and AIDS drugs for poor countries that can't afford to pay Western prices.


The 6-year-old case that just wrapped up in the Supreme Court revolves around a legal provision in India's 2005 patent law that is aimed at preventing companies from getting fresh patents for making only minor changes to existing medicines — a practice known as "evergreening."


Novartis' argued that a new version of Glivec — marketed in the U.S. as Gleevec — was a significant change from the earlier version because it was more easily absorbed by the body.


India's Patent Controller turned down the application, saying the change was an obvious development, and the new medicine was not sufficiently distinct from the earlier version to warrant a patent extension.


Patient advocacy groups hailed the decision as a blow to "evergreening."


But Western companies argued that India's generic manufacturers were cutting the incentive for major drug makers to invest in research and innovation if they were not going to be able to reap the exclusive profits that patents bring.


"This case is about safeguarding incentives for better medicines so that patients' needs will be met in the future," says Eric Althoff, a Novartis spokesman.


International drug companies have accused India of disregarding intellectual property rights, and have pushed for stronger patent protection that would weaken India's generics industry.


Earlier this year, an Indian manufacturer was allowed to produce a far cheaper version of the kidney and liver cancer treatment sorefinib, manufactured by Bayer Corp.


Bayer was selling the drug for about $5,600 a month. Natco, the Indian company, said its generic version would cost $175 a month, less than 1/30th as much. Natco was ordered to pay 6 percent in royalties to Bayer.


Novartis says the outcome of the new case will not affect the availability of generic versions of Glivec because it is covered by a grandfather clause in India's patent law. Only the more easily absorbed drug would be affected, Althoff said, adding that its own generic business, Sandoz, produces cheap versions of its drugs for millions across the globe.


Public health activists say the question goes beyond Glivec to whether drug companies should get special protection for minor tweaks to medicines that others could easily have uncovered.


"We're looking to the Supreme Court to tell Novartis it won't open the floodgates and allow abusive patenting practices," said Eldred Tellis, of the Sankalp Rehabilitation Centre, a private group working with HIV patients.


The court's decision is expected to be a landmark that will influence future drug accessibility and price across the developing world.


"We're already paying very high prices for some of the new drugs that are patented in India," said Petros Isaakidis, an epidemiologist with Doctors Without Borders. "If Novartis' wins, even older medicines could be subject to patenting again, and it will become much more difficult for us in future to provide medicines to our patients being treated for HIV, hepatitis and drug resistant TB."


Read More..